 | | Vol. 12.43 – 5 November, 2020 |
| |
|
|
| An intelligent biomimetic nanoplatform was designed based on dendritic large-pore mesoporous silica nanoparticles for suppressing metastatic TNBC by combining photothermal ablation and immune remodeling.
[ACS Nano] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists interrogated transcriptome data from primary breast tumors and found that among genes in 17q23, PRR11 was a key gene associated with a poor response to therapeutic estrogen suppression.
[Nature Communications] |
|
|
|
| Researchers identified a lncRNA, DILA1, which interacted with Cyclin D1 and was overexpressed in tamoxifen-resistant breast cancer cells.
[Nature Communications] |
|
|
|
| Investigators showed that recurrent mammary tumors exhibited global changes in gene expression and histone modifications and acquired dependence on the G9a histone methyltransferase.
[Cell Reports] |
|
|
|
| Researchers conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts.
[Oncogene] |
|
|
|
| In vitro, experiments revealed that knockdown of RNA binding motif protein 7 (RBM7) dramatically inhibited breast cancer cell proliferation, while inducing G1 cell cycle arrest; the opposite was true when RBM7 was overexpressed.
[npj Breast Cancer] |
|
|
|
| The authors developed and characterized the efficacy of novel AMPK activator that selectively induced oxidative phosphorylation and decreased glycolysis in TNBC cells, while not affecting these pathways in normal cells.
[British Journal of Cancer] |
|
|
|
| The transcriptomes of primary tumors and metastases in mice harboring estrogen receptor+ breast cancer patient-derived xenografts were analyzed following single-cell RNAseq. In vitro assays were employed to delineate mechanisms of endocrine resistance and stemness.
[British Journal of Cancer] |
|
|
|
| Scientists found that eEF-2K, which was overexpressed in cancer cells and was required for survival of stressed cells, was involved in the negative-feedback activation of Akt and cytoprotective autophagy induction in breast cancer cells in response to mTOR inhibitors.
[Cell Death & Disease] |
|
|
|
| Researchers characterized the fingerprint profiles of 22 ginger samples using liquid chromatography-mass spectroscopy, followed by a principal component analysis and pearson correlation analysis. They also evaluated the anti-proliferative effects of these samples on TNBC cells using the MTT assays.
[Scientific Reports] |
|
|
|
| Investigators outlined the role and function of cancer-associated fibroblast-derived extracellular vesicles carrying miR-1-3p in breast cancer. They first experimentally determined downregulated miR-1-3p in breast cancer tissues.
[Cancer Gene Therapy] |
|
|
|
| Researchers assessed the potential of mesenchymal stem cells in the stimulation of PD‐L1 expression in a low PD‐L1 breast cancer cell line and explored its associated cytokine.
[Journal of Cellular Physiology] |
|
|
|
|
| Investigators describe the features of tumor microenvironment within the primitive breast cancer, throughout its evolution and spread into the main metastatic sites.
[International Journal of Molecular Sciences] |
|
|
|
| The mechanism of intracellular centrosome amplification, the impact of which on breast cancer and the latest breast cancer target treatment options for centrosome amplification are exhaustively elaborated in this review.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| Everest Medicines announced that the first patient has been dosed in China into the EVER-132-001 Phase IIb registration clinical trial evaluating TrodelvyTM for the treatment of patients with metastatic TNBC Everest Medicines who have received at least two prior therapies for metastatic disease.
[Everest Medicines] |
|
|
|
| Covera Health announced the integration of ScreenPoint Medical’s artificial intelligence tools into its quality analytics platform. Covera Health planned to leverage these tools to improve early detection of breast cancer for both patients and providers.
[Covera Health (Business Wire Inc)] |
|
|
|
|
| April 9 – April 14, 2021
Washington, DC, United States |
|
|
|
|
|
| | Pfizer – Cambridge, Massachusetts |
|
|
|
| | Cancer Research UK Cambridge Institute – Cambridge, England, United Kingdom |
|
|
|
| | University of North Dakota – Grand Forks, North Dakota, United States |
|
|
|
| | IRCCS Candiolo Cancer Institute – Candiolo, Italy |
|
|
|
| | University of Oslo – Oslo, Norway |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
